Abstract
Nude mice bearing xenografts of HT-29 human colon cancer cell line were treated for 4 weeks with somatostatin analog (RC-160), bombesin/gastrin releasing peptide (GRP) antagonists (RC-3095 and RC-3440). In three separate experiments somatostatin analog RC-160 (50 μg/day) released from microgranules significantly reduced tumor growth. Bombesin/GRP antagonists, RC-3095 and RC-3440 injected subcutaneously (s.c.) twice daily at a dose of 10 μg had the greatest and consistently significant inhibitory effect on tumor growth. RC-3095 given once daily s.c. at a dose of 20 μg was less effective. RC-3095 also inhibited metastatic tumor growth after intrasplenic injection of HT-29 cells in nude mice. Specific binding sites of somatostatin, bombesin and epidermal growth factor (EGF) were detected on intact HT-29 cells or on the membranes from HT-29 tumor xenografts. The inhibitory effects of bombesin antagonists on tumor growth were consistently linked with a significant down-regulation of EGF receptors. Bombesin/GRP antagonists and somatostatin analogs could be considered for the development of new hormonal therapies for colon cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 693-701 |
| Number of pages | 9 |
| Journal | Acta Oncologica |
| Volume | 33 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jan 1 1994 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Oncology
- Radiology Nuclear Medicine and imaging
- Hematology
Cite this
Inhibitory effects of antagonists of bombesin/gastrin releasing peptide (GRP) and somatostatin analog (RC-160) on growth of HT-29 human colon cancers in nude mice. / Radulovic, Sinisa; Schally, Andrew V; Reile, Herta; Halmos, Gabor; Szepeshazi, Karoly; Groot, Kate; Milovanovic, Slobodan; Miller, Glenn; Yano, Tetsu.
In: Acta Oncologica, Vol. 33, No. 6, 01.01.1994, p. 693-701.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Inhibitory effects of antagonists of bombesin/gastrin releasing peptide (GRP) and somatostatin analog (RC-160) on growth of HT-29 human colon cancers in nude mice
AU - Radulovic, Sinisa
AU - Schally, Andrew V
AU - Reile, Herta
AU - Halmos, Gabor
AU - Szepeshazi, Karoly
AU - Groot, Kate
AU - Milovanovic, Slobodan
AU - Miller, Glenn
AU - Yano, Tetsu
PY - 1994/1/1
Y1 - 1994/1/1
N2 - Nude mice bearing xenografts of HT-29 human colon cancer cell line were treated for 4 weeks with somatostatin analog (RC-160), bombesin/gastrin releasing peptide (GRP) antagonists (RC-3095 and RC-3440). In three separate experiments somatostatin analog RC-160 (50 μg/day) released from microgranules significantly reduced tumor growth. Bombesin/GRP antagonists, RC-3095 and RC-3440 injected subcutaneously (s.c.) twice daily at a dose of 10 μg had the greatest and consistently significant inhibitory effect on tumor growth. RC-3095 given once daily s.c. at a dose of 20 μg was less effective. RC-3095 also inhibited metastatic tumor growth after intrasplenic injection of HT-29 cells in nude mice. Specific binding sites of somatostatin, bombesin and epidermal growth factor (EGF) were detected on intact HT-29 cells or on the membranes from HT-29 tumor xenografts. The inhibitory effects of bombesin antagonists on tumor growth were consistently linked with a significant down-regulation of EGF receptors. Bombesin/GRP antagonists and somatostatin analogs could be considered for the development of new hormonal therapies for colon cancer.
AB - Nude mice bearing xenografts of HT-29 human colon cancer cell line were treated for 4 weeks with somatostatin analog (RC-160), bombesin/gastrin releasing peptide (GRP) antagonists (RC-3095 and RC-3440). In three separate experiments somatostatin analog RC-160 (50 μg/day) released from microgranules significantly reduced tumor growth. Bombesin/GRP antagonists, RC-3095 and RC-3440 injected subcutaneously (s.c.) twice daily at a dose of 10 μg had the greatest and consistently significant inhibitory effect on tumor growth. RC-3095 given once daily s.c. at a dose of 20 μg was less effective. RC-3095 also inhibited metastatic tumor growth after intrasplenic injection of HT-29 cells in nude mice. Specific binding sites of somatostatin, bombesin and epidermal growth factor (EGF) were detected on intact HT-29 cells or on the membranes from HT-29 tumor xenografts. The inhibitory effects of bombesin antagonists on tumor growth were consistently linked with a significant down-regulation of EGF receptors. Bombesin/GRP antagonists and somatostatin analogs could be considered for the development of new hormonal therapies for colon cancer.
UR - http://www.scopus.com/inward/record.url?scp=0028028369&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028028369&partnerID=8YFLogxK
U2 - 10.3109/02841869409121784
DO - 10.3109/02841869409121784
M3 - Article
C2 - 7946450
AN - SCOPUS:0028028369
VL - 33
SP - 693
EP - 701
JO - Acta Oncologica
JF - Acta Oncologica
SN - 0284-186X
IS - 6
ER -